Previous Close | 13.32 |
Open | 13.45 |
Bid | 13.30 x 1400 |
Ask | 13.35 x 4000 |
Day's Range | 13.26 - 13.30 |
52 Week Range | 7.09 - 13.93 |
Volume | |
Avg. Volume | 10,844,593 |
Market Cap | 14.914B |
Beta (5Y Monthly) | 1.04 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.50 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Nov 27, 2017 |
1y Target Est | 15.13 |
Subscribe to Yahoo Finance Plus to view Fair Value for TEVA
AstraZeneca’s move on Monday to cap at $35 the out-of-pocket costs that patients pay for the company’s Symbicort inhaler speaks to the political and regulatory pressure coming to bear on manufacturers of certain commonly used but expensive treatments. The British drugmaker’s shift follows a similar step last month by Boehringer Ingelheim, which sells rival inhalers including Atrovent and Spiriva. Sen. Bernie Sanders, the independent from Vermont, launched an investigation of inhaler prices in January.
Eliyahu Kalif, Executive Vice President and Chief Financial Officer of Teva Pharmaceutical Industries Ltd (NYSE:TEVA), has sold 77,550 shares of the company on March 6, 2024, according to a recent SEC filing.
SHANGHAI & TEL AVIV, Israel, February 26, 2024--Teva Pharmaceutical Investments Singapore Pte Ltd (TPIS), a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Jiangsu Nhwa Pharmaceutical Co., Ltd ("Nhwa") today announced it formed a partnership for the marketing and distribution of Teva’s AUSTEDO (deutetrabenazine) for the treatment of neurodegenerative and movement disorders - chorea associated with Huntington’s disease (HD) and tardive dyskinesia (TD) in adults. The pa